CYTOGENETIC ABNORMALITIES IN POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: CORRELATIONS WITH GENOTYPE AND PHENOTYPE IN THE MYSEC STUDY

被引：0

作者：

Mora, B.

Giorgino, T.

Guglielmelli, P.

Rumi, E.

Maffioli, M.

Rambaldi, A.

Caramella, M.

Komrokji, R.

Gotlib, J.

Kiladjian, J. J.

Cervantes, F.

Devos, T.

Palandri, F.

De Stefano, V.

Ruggeri, M.

Silver, R. T.

Benevolo, G.

Albano, F.

Caramazza, D.

Merli, M.

Pietra, D.

Casalone, R.

Barbui, T.

Rotunno, G.

Cazzola, M.

Vannucchi, A. M.

Passamonti, F.

机构：

[1] Univ Insubria, Dept Med & Surg, Hematol, ASST Sette Laghi, Varese, Italy

[2] Univ Florence, Azienda Osped Univ Careggi, Natl Res Council Italy, Inst Neurosci,Dept Expt & Clin Med,CRIMM, Florence, Italy

[3] Univ Pavia, Fdn IRCCS Policlin San Matteo, Dept Hematol Oncol, Pavia, Italy

[4] Univ Insubria, ASST Sette Laghi, Osped Circolo, Dept Med & Surg, Varese, Italy

[5] Univ Milan, Osped Niguarda Ca Granda, ASST Papa Giovanni XXIII, Hematol & BMT Unit, Milan, Italy

[6] Stanford Univ, Moffit Canc Ctr, Stanford, CA 94305 USA

[7] Hop St Louis, St Louis, France

[8] Univ Paris Diderot, Paris, France

[9] Univ Barcelona, Hosp Clin, IDIBAPS, Barcelona, Spain

[10] Katholieke Univ Leuven, Dept Hematol, Univ Hosp Leuven, Leuven, Belgium

[11] Katholieke Univ Leuven, Dept Microbiol & Immunol, Lab Expt Transplantat, Leuven, Belgium

[12] St Orsola Marcello Malpighi Hosp, Bologna, Italy

[13] Univ Cattolica Sacro Cuore, Milan, Italy

[14] Osped S Bortolo, Vicenza, Italy

[15] Weill Cornell Med Coll, New York, NY USA

[16] Ctr Oncol Ematol Subalpino COES, Rome, Italy

[17] Univ Bari, Bari, Italy

[18] Osped Circolo Varese, ASST Sette Laghi, Cytogenet & Med Genet Lab, Varese, Italy

[19] Univ Florence, Azienda Osped Univ Careggi, Dept Expt & Clin Med, FROM Res Fdn,ASST Papa Giovanni XXIII,CRIMM, Florence, Italy

[20] Univ Pavia, Dept Hematol Oncol, Fdn IRCCS Policlin San Matteo, Pavia, Italy

[21] Univ Florence, Azienda Osped Univ Careggi, Dept Expt & Clin Med, Ctr Ric & Innovaz Malattie Mieloproliferat, Florence, Italy

来源：

HAEMATOLOGICA | 2017年 / 102卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

B006

引用

页码：3 / 4

页数：2

共 50 条

[31] Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia
Mora, Barbara
Giorgino, Toni
Guglielmelli, Paola
Rumi, Elisa
Maffioli, Margherita
Rambaldi, Alessandro
Caramella, Marianna
Komrokji, Rami
Gotlib, Jason
Kiladjian, Jean Jacques
Cervantes, Francisco
Devos, Timothy
Palandri, Francesca
De Stefano, Valerio
Ruggeri, Marco
Silver, Richard T.
Benevolo, Giulia
Albano, Francesco
Cavalloni, Chiara
Barraco, Daniela
Pietra, Daniela
Barbui, Tiziano
Rotunno, Giada
Vannucchi, Alessandro Maria
Passamonti, Francesco
LEUKEMIA RESEARCH, 2018, 69 : 100 - 102
[32] Phase II Study of Sunitinib in Patients With Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
Apostolidou, Effrosyni
Kantarjian, Hagop
Thomas, Deborah
Burger, Ian
Borthakur, Gautam
Verstovsek, Srdan
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (04): : 281 - 284
[33] A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Primary Myelofibrosis, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis
Shah, Neil P.
Olszynski, Patrycja
Sokol, Lubomir
Verstovsek, Srdan
Hoffman, Ronald
List, Alan F.
Cortes, Jorge
Kantadian, Hagop M.
Gilliland, D. Gary
Clary, Douglas O.
Bui, Lynne A.
Wadleigh, Martha
BLOOD, 2008, 112 (11) : 44 - 44
[34] IMPACT OF DRIVER AND HIGH MOLECULAR RISK MUTATIONS ON CLINICAL PHENOTYPE AND PROGNOSIS IN PATIENTS WITH POST-POLYCYTHEMIA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN AGIMM STUDY
Rotunno, G.
Pacilli, A.
Guglielmelli, P.
Brogi, G.
Artusi, V.
Rumi, E.
Delaini, F.
Mannarelli, C.
Biamonte, F.
Maffioli, M.
Fjerza, R.
Pieri, L.
Pietra, D.
Belotti, C.
Bosi, A.
Tagliafico, E.
Manfredini, R.
Bernardis, I.
Passamonti, F.
Rambaldi, A.
Barbui, T.
Cazzola, M.
Vannucchi, A. M.
HAEMATOLOGICA, 2015, 100 : 44 - 45
[35] THE HIGH MOLECULAR RISK (HMR) STATUS DOES NOT ACCURATELY PREDICT POOR OUTCOME IN PATIENTS WITH POST-ESSENTIAL THROMBOCYTHEMIA AND POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Guglielmelli, P.
Coltro, G.
Rotunno, G.
Romagnoli, S.
Maccari, C.
Paoli, C.
Gesullo, F.
Loscocco, G. G.
Vannucchi, A. M.
HAEMATOLOGICA, 2021, 106 (10) : 82 - 82
[36] Validation of the Myelofibrosis Secondary to PV and ET-Prognostic Model in Patients with Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: MD Anderson Cancer Center
Masarova, Lucia
Bose, Prithviraj
Pemmaraju, Naveen
Daver, Naval
Cortes, Jorge E.
Estrov, Zeev
Kantarjian, Hagop M.
Verstovsek, Srdan
BLOOD, 2017, 130
[37] Efficacy and safety of JAK inhibitor INC424 in patients with primary and post-polycythemia vera or post-essential thrombocythemia myelofibrosis in the Chinese population
Xin Du
Daobin Zhou
Frontiers of Medicine, 2016, 10 : 437 - 443
[38] Efficacy and safety of JAK inhibitor INC424 in patients with primary and post-polycythemia vera or post-essential thrombocythemia myelofibrosis in the Chinese population
Xin Du
Daobin Zhou
Frontiers of Medicine, 2016, 10 (04) : 437 - 443
[39] Efficacy and safety of JAK inhibitor INC424 in patients with primary and post-polycythemia vera or post-essential thrombocythemia myelofibrosis in the Chinese population
Du, Xin
Zhou, Daobin
FRONTIERS OF MEDICINE, 2016, 10 (04) : 437 - 443
[40] The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis
Hernandez-Boluda, Juan-Carlos
Pereira, Arturo
Gomez, Montse
Boque, Concepcion
Ferrer-Marin, Francisca
Raya, Jose-Maria
Garcia-Gutierrez, Valentin
Kerguelen, Ana
Xicoy, Blanca
Barba, Pere
Martinez, Jesus
Luno, Elisa
Alvarez-Larran, Alberto
Martinez-Lopez, Joaquin
Arbelo, Elisa
Besses, Carles
HAEMATOLOGICA, 2014, 99 (04) : E55 - E57

← 1 2 3 4 5 →